Hemab Therapeutics and Seaport Therapeutics are the newest biotech companies to join the public markets, each with an upsized IPO. According to IPO research firm Renaissance Capital, April was the biggest month for biotech IPO proceeds in more than five years. Here’s a look at the two newest biotech companies that joined the Nasdaq on Friday. ... How to turn analytics into actual policy outcomes. ... Hemab develops drugs for rare bleeding disorders. The company’s lead disease target is Glanzmann thomboasthenia, a genetic disorder that results in improperly functioning platelets. In Phase 1/2 testing, Hemab reported a significant reduction in the annualized treated bleed rate, according to the IPO filing. Sutacimig’s Phase 3 study is expected to begin in the second half of this year. A Phase 2 test of sutacimig is ongoing in a different disorder, Factor VII deficiency. Hemab expects to report clinical data from this study late this year or early next year. Hemab’s next drug candidate, HMB-002, is in development as a prophylactic treatment for von Willebrand disease, a disorder in which patients have low levels of von Willebrand factor (VWF). With that capital and the IPO proceeds, Hemab plans to spend $120 million to $130 million for clinical testing of sutacimig in Glanzmann thrombasthenia and Factor VII deficiency; $60 million to $70 million on clinical testing of HMB-002 for Von Willebrand disease; and $25 million to $35 million for other programs. This past week closed with three biotech companies joining the public markets, a flurry of activity that helped make April the biggest month for biotech IPOs since March 2021, according to Renaissance Capital.

If you’re looking for a sign that biotech’s IPO renaissance remains on track then the pair of upsized Nasdaq listings on Friday morning is a good place to start. | "We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce. The IPO funds are expected to help finance a phase 3 study in Glanzmann thrombasthenia, as well as an ongoing phase 2 trial in another bleeding disorder called Factor VII deficiency. Meanwhile, Hemab wants to push its monovalent antibody, HMB-002, through a phase 1/2 study for von Willebrand disease, another genetic disorder that impacts blood clotting. Seaport Therapeutics Hemab Therapeutics IPO biotech IPO Biotech Zohar co-founded Karuna Therapeutics, the neuroscience biotech bought by Bristol Myers Squibb for $14 billion to acquire the schizophrenia drug that would hit the market as Cobenfy. When asked by Fierce why Seaport hadn’t also opted for a Big Pharma acquisition, Zohar suggested that companies try and keep both options open. Both depression-focused Seaport Therapeutics and clotting company Hemab Therapeutics had been priming investors earlier this week to expect IPOs of around the $180 million range. But the companies significantly overshot their targets. Boston-based Seaport sold nearly 14.2 million shares for its offering—flying past the 11.8 million shares that the company had been expecting as recently as Monday. With the shares priced at $18 apiece, it means the biotech will rake in $254.9 million in gross proceeds from the IPO. Seaport’s stock began trading on the Nasdaq this morning under the ticker “SPTX.” It was joined by another biotech entrant in the form of Hemab. Like Seaport, Hemab had been banking on an IPO of around $180 million, but the end result has come out above $300 million, according to an April 30 release.

Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining momentum. Both Seaport and Hemab are hoping to bring in around $180 million from their listings, in the latest sign that biotech IPOs are regaining momentum. The biotech has already tested sutacimig in Glanzmann thrombasthenia, a rare genetic bleeding disorder caused by a deficiency of the platelet integrin alpha IIb beta3, which prevents blood from properly clotting. Hemab has previously pointed to phase 2 study as demonstrating that sutacimig achieved clinically meaningful bleeding reduction in these patients. The IPO funds would help finance a phase 3 study in Glanzmann thrombasthenia, as well as an ongoing phase 2 trial in another bleeding disorder called Factor VII deficiency. Should the final share price fall in the middle of this range, the biotech expects the IPO to bring in $183.5 million in net proceeds—rising to $211.4 million if underwriters fully take up their 30-day offer to buy an additional 1.77 million shares at the same price. The biotech employs 58 people and was originally assembled by PureTech Health—where Zohar was previously CEO—and supplied with $100 million when it launched in the spring of 2024. Seaport followed that up with a $225 million series B a few months later. Out of the $325 million raised to date, Seaport entered 2026 with a hefty chunk of funds—$233.7 million, to be precise—still intact. When combining these funds with the IPO proceeds, Seaport said today that it has earmarked $121 million to advance its lead depression candidate SPT-300, also known as GlyphAllo.